Bon Natural Life Limited revenue by segment BON
Annual
Quarterly
Bon Natural Life Limited splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Sep 30, 2025 was Fragrance Compounds at $8.1 million, 43% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
|---|---|---|---|---|---|
| Revenue |
19
|
24
|
30
|
30
|
25
|
| Fragrance Compounds |
8
+63.5%
share 43.3%
|
5
-65.5%
share 20.7%
|
14
+4.4%
share 48.5%
|
14
share 45.8%
|
—
|
| Bioactive Food Ingredients |
7
-40.3%
share 38.9%
|
12
+87.0%
share 51.0%
|
7
-28.2%
share 22.0%
|
9
+48.5%
share 30.3%
|
6
share 23.9%
|
| Health Supplements Solid Drinks |
3
-50.6%
share 17.8%
|
7
-22.6%
share 28.3%
|
9
+21.8%
share 29.5%
|
7
+7.4%
share 23.9%
|
7
share 26.1%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- BON (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- Cayman Islands
- Headquarters
- Shaanxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1816815
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.